Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) saw strong trading volume on Monday . 969,262 shares traded hands during mid-day trading, a decline of 8% from the previous session’s volume of 1,056,906 shares.The stock last traded at $2.10 and had previously closed at $1.92.

Several equities analysts have recently commented on the company. Maxim Group set a $4.00 price objective on AEterna Zentaris and gave the company a “buy” rating in a research report on Friday, August 11th. ValuEngine upgraded AEterna Zentaris from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $4.33.

A hedge fund recently raised its stake in AEterna Zentaris stock. JPMorgan Chase & Co. boosted its stake in shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,800 shares of the biopharmaceutical company’s stock after acquiring an additional 46,500 shares during the quarter. JPMorgan Chase & Co. owned 0.35% of AEterna Zentaris worth $120,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 2.37% of the stock is currently owned by institutional investors.

WARNING: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.